Paraoxonase Enzyme Activity Is Enhanced by Zinc Supplementation in Hemodialysis Patients

REFERENCES

• Bevc S, Sabic S, Hojs R. Atherosclerosis in hemodialysis patients – the role of microinflammation. Ren Fail. 2008; 30(10):1012–1016.
   PubMed Web of Science ®Google Scholar
• Houtman JP. Trace elements and cardiovascular diseases. J Cardiovasc Risk. 1996;3(1):18–25.
   PubMedGoogle Scholar
• Aalbers TG, Houtman JP. Relationships between trace elements and atherosclerosis. Sci Total Environ. 1985;43(3):255–283.
   PubMedGoogle Scholar
• Brewer LC, Michos ED, Reis JP. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets. 2011;12(1):54–60.
   PubMedGoogle Scholar
• Chitalia N, Recio-Mayoral A, Kaski JC, Banerjee D. Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis. 2012;220(1):265–268.
   PubMed Web of Science ®Google Scholar
• Cozzolino M, Ketteler M, Zehnder D. The vitamin D system: A crosstalk between the heart and kidney. Eur J Heart Fail. 2010;12(10):1031–1041.
   PubMed Web of Science ®Google Scholar
• Rossowska MJ, Ghanaei P, Nakamoto T. Effect of dietary caffeine and zinc on the activity of antioxidant enzymes, zinc, and copper concentration of the heart and liver in fast-growing rats. Biol Trace Elem Res. 1995;50(3):229–236.
   PubMedGoogle Scholar
• Noleto Magalhaes RC, Guedes Borges de Araujo C, Batista de Sousa Lima V, Machado Moita Neto J, do Nascimento Nogueira N, do Nascimento Marreiro D. Nutritional status of zinc and activity superoxide dismutase in chronic renal patients undergoing hemodialysis. Nutr Hosp. 2011;26(6):1456–1461.
   PubMedGoogle Scholar
• Ongajooth L, Ongajyooth S, Likidlilid A, Chantachum Y, Shayakul C, Nilwarangkur S. Role of lipid peroxidation, trace elements and anti-oxidant enzymes in chronic renal disease patients. J Med Assoc Thai. 1996;79(12):791–800.
   PubMedGoogle Scholar
• Koca T, Berber A, Koca HB, Demir TA, Koken T. Effects of hemodialysis period on levels of blood trace elements and oxidative stress. Clin Exp Nephrol. 2010;14(5):463–468.
   PubMedGoogle Scholar
• Wratten ML, Galaris D, Tetta C, Sevanian A. Evolution of oxidative stress and inflammation during hemodialysis and their contribution to cardiovascular disease. Antioxid Redox Signal. 2002;4(6):935–944.
   PubMedGoogle Scholar
• Ivanovski O, Nikolov IG, Drueke BT, Massy AZ. Atherosclerosis and vascular calcification in uraemia – a new experimental model. Prilozi. 2007;28(2):11–24.
   PubMedGoogle Scholar
• Segarra A, Chacon P, Martin M, . Serum lipoprotein (a) levels in patients with chronic renal failure – evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: A prospective study. Nephron. 1995; 69(1):9–13.
   PubMedGoogle Scholar
• Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21(6):573–592.
   PubMed Web of Science ®Google Scholar
• Maheshwari N, Ansari MR, Darshana MS, Lal K, Ahmed K. Pattern of lipid profile in patients on maintenance hemodialysis. Saudi J Kidney Dis Transpl. 2010;21(3):565–570.
   PubMedGoogle Scholar
• Tepel M, Echelmeyer M, Orie NN, Zidek W. Increased intracellular reactive oxygen species in patients with end-stage renal failure: Effect of hemodialysis. Kidney Int. 2000;58(2):867–872.
   PubMedGoogle Scholar
• Bonomini M, Stuard S, Carreno MP, . Neutrophil reactive oxygen species production during hemodialysis: Role of activated platelet adhesion to neutrophils through P-selectin. Nephron. 1997;75(4):402–411.
   PubMedGoogle Scholar
• Nunez-Cordoba JM, Martinez-Gonzalez MA. Antioxidant vitamins and cardiovascular disease. Curr Top Med Chem. 2011;11(14):1861–1869.
   PubMed Web of Science ®Google Scholar
• Meurs I, Van Eck M, Van Berkel TJ. High-density lipoprotein: Key molecule in cholesterol efflux and the prevention of atherosclerosis. Curr Pharm Des. 2010;16(13):1445–1467.
   PubMedGoogle Scholar
• Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8(4):222–232.
   PubMed Web of Science ®Google Scholar
• Shamir R, Hartman C, Karry R, . Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: Selective secretion of PON1 and PON2. Free Radic Biol Med. 2005;39(3):336–344.
   PubMedGoogle Scholar
• Forte TM, Oda MN, Knoff L, . Targeted disruption of the murine lecithin: Cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. J Lipid Res. 1999;40(7):1276–1283.
   PubMedGoogle Scholar
• Fuhrman B, Volkova N, Aviram M. Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis. 2005; 180(1):55–61.
   PubMedGoogle Scholar
• Deakin S, Moren X, James RW. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis. 2005;179(1):17–25.
   PubMedGoogle Scholar
• Aviram M, Hardak E, Vaya J, . Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000;101(21): 2510–2517.
   PubMed Web of Science ®Google Scholar
• Watson AD, Berliner JA, Hama SY, . Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96(6):2882–2891.
   PubMedGoogle Scholar
• Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104(1–2):129–135.
   PubMed Web of Science ®Google Scholar
• Kaplan M, Aviram M. Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med. 1999;37(8):777–787.
   PubMed Web of Science ®Google Scholar
• Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: Studies in PON1-knockout mice. Free Radic Biol Med. 2003;34(6):774–784.
   PubMedGoogle Scholar
• Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis. 2006;187(1):74–81.
   PubMed Web of Science ®Google Scholar
• McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem. 1986;32(4):671–673.
   PubMedGoogle Scholar
• MacKness B, Mackness MI, Durrington PN, . Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest. 2000;30(1):4–10.
   PubMedGoogle Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
   PubMed Web of Science ®Google Scholar
• Abuja PM, Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta. 2001;306(1–2):1–17.
   PubMed Web of Science ®Google Scholar
• Bao B, Prasad AS, Beck FW, . Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: A potential implication of zinc as an atheroprotective agent. Am J Clin Nutr. 2010;91(6):1634–1641.
   PubMed Web of Science ®Google Scholar
• Jenner A, Ren M, Rajendran R, . Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. Free Radic Biol Med. 2007;42(4):559–566.
   PubMed Web of Science ®Google Scholar
• Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F. Imbalance of oxidants and antioxidants in hemodialysis patients. Blood Purif. 1999;17(2–3):99–106.
   PubMedGoogle Scholar
• Rysz J, Potargowicz E, Banach M, . Increased whole blood chemiluminescence in patients with chronic renal failure independent of hemodialysis treatment. Arch Immunol Ther Exp (Warsz). 2006;54(5):347–355.
   PubMedGoogle Scholar
• Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62(5):1524–1538.
   PubMed Web of Science ®Google Scholar
• Drueke TB, Nguyen Khoa T, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int Suppl. 2001;78:S114–S119.
   PubMedGoogle Scholar
• Mitra S, Deshmukh A, Sachdeva R, Lu J, Mehta JL. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am J Med Sci. 2011;342(2):135–142.
   PubMed Web of Science ®Google Scholar
• Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84(4):1381–1478.
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: Focus on antioxidative activities. Curr Opin Lipidol. 2010;21(4):312–318.
   PubMed Web of Science ®Google Scholar
• Shoji T, Nishizawa Y. Plasma lipoprotein abnormalities in hemodialysis patients – clinical implications and therapeutic guidelines. Ther Apher Dial. 2006;10(4):305–315.
   PubMedGoogle Scholar
• Kushiya F, Wada H, Sakakura M, . Effects of lipid abnormalities on arteriosclerosis and hemostatic markers in patients under hemodialysis. Clin Appl Thromb/Hemost. 2003; 9(3):203–210.
   PubMedGoogle Scholar
• Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JA. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 1994;33(3):832–839.
   PubMedGoogle Scholar
• Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem/FEBS. 1993;211(3):871–879.
   PubMedGoogle Scholar
• Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(4): 473–480.
   PubMed Web of Science ®Google Scholar
• Sumegova K, Blazicek P, Waczulikova I, Zitnanova I, Durackova Z. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks. Acta Biochim Pol. 2006;53(4):783–787.
   PubMedGoogle Scholar
• Aviram M, Kaplan M, Rosenblat M, Fuhrman B. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharmacol. 2005;170:263–300.
   PubMedGoogle Scholar
• Ikeda Y, Suehiro T, Itahara T, . Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol. 2007;67(6):358–365.
   PubMedGoogle Scholar
• Saeed SA, Elsharkawy M, Elsaeed K, Fooda O. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int. 2008;12(4):471–479.
   PubMedGoogle Scholar
• Suehiro T, Ikeda Y, Shiinoki T, . Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb. 2002;9(3):133–138.
   PubMedGoogle Scholar
• Itahara T, Suehiro T, Ikeda Y, . Serum paraoxonase and arylesterase activities in hemodialysis patients. J Atheroscler Thromb. 2000;7(3):152–158.
   PubMedGoogle Scholar
• Lahrach H, Ghalim N, Taki H, . Serum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysis. J Clin Lipidol. 2008;2(1):43–50.
   PubMedGoogle Scholar
• Kotur-Stevuljevic J, Simic-Ogrizovic S, Dopsaj V, . A hazardous link between malnutrition, inflammation and oxidative stress in renal patients. Clin Biochem. 2012. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0009-9120%2812%2900206-8. Accessed August 18, 2012.
   Google Scholar
• Navarro-Alarcon M, Reyes-Perez A, Lopez-Garcia H, Palomares-Bayo M, Olalla-Herrera M, Lopez-Martinez MC. Longitudinal study of serum zinc and copper levels in hemodialysis patients and their relation to biochemical markers. Biol Trace Elem Res. 2006;113(3):209–222.
   PubMed Web of Science ®Google Scholar
• Szpanowska-Wohn A, Kolarzyk E, Chowaniec E. Estimation of intake of zinc, copper and iron in the diet of patients with chronic renal failure treated by hemodialysis. Biol Trace Elem Res. 2008;124(2):97–102.
   PubMedGoogle Scholar
• Zwolinska D, Grzeszczak W, Kilis-Pstrusinska K, Szprynger K, Szczepanska M. Lipid peroxidation and antioxidant enzymes in children with chronic renal failure. Pediatr Nephrol. 2004;19(8):888–892.
   PubMedGoogle Scholar
• Yanagisawa H. Zinc deficiency and clinical practice – validity of zinc preparations. Yakugaku Zasshi. 2008;128(3):333–339.
   PubMedGoogle Scholar
• Barceloux DG. Zinc. J Toxicol Clin Toxicol. 1999;37(2): 279–292.
   PubMed Web of Science ®Google Scholar
• Wratten ML, Tetta C, Ursini F, Sevanian A. Oxidant stress in hemodialysis: Prevention and treatment strategies. Kidney Int Suppl. 2000;76:S126–S132.
   PubMedGoogle Scholar
• Powell SR. The antioxidant properties of zinc. J Nutr. 2000;130(5S Suppl):1447S–1454S.
   PubMedGoogle Scholar